Consulting Report

Lewis, F.

Consulting Report
October 2015

The estimates of future cases of dementia are a result of work commissioned by Alzheimer’s Research UK. The estimates were based on three components:

O'Neill, P. and Sussex, J.

Consulting Report
May 2015

The OHE undertook an analysis of the uptake of medicines in 13 high income countries. The UK perspective on this was published in November 2014 by the ABPI. OHE has been commissioned by LIF, the trade association of the pharmaceutical industry in Sweden, to reanalyse the international comparison of medicines uptake from the Swedish perspective; and the results are available here and on LIF’s website.

Chapman, A. and Karlsberg Schaffer, S.

Consulting Report
March 2015

A new OHE Consulting Report considers the data capabilities in the UK for monitoring medicine use according to indication using real world data.

Shah, K., Chapman, A., Devlin, N. and Barnsley, P.

Consulting Report
February 2015

Stated preference studies are increasingly being used to understand people’s views about the relative importance of different criteria for making health care priority setting decisions.

Rejon-Parrilla, J.C., Garau, M. and Sussex, J.

Consulting Report
September 2014

Obstructive sleep apnoea (OSA) is the temporary cessation of breathing during sleep because of a narrowing or closure of the pharyngeal airway. Untreated OSA can result in daytime sleepiness that affects cognitive function, mood and quality of life and can increase the risks of road traffic, work-related accidents and cardiovascular disease and strokes.

Lewis, F., Karlsberg Schaffer, S., Sussex, J., O'Neill, P. and Cockcroft, L.

Consulting Report
June 2014

Alzheimer’s Research UK commissioned OHE Consulting to model the incidence and cost of dementia in the UK and the potential impact of better treatment. The analyses estimate the extent of the substantial reductions in health and social care costs that are possible to 2050.

Rejon-Parrilla, J.C., Hernandez-Villafuerte, K., Shah, K., Mestre-Ferrandiz, J., Garrison, L. and Towse, A.

Consulting Report
May 2014

This report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. Included are the ten cancer drugs approved by the EMA during 2003–2005. Decisions by France’s HAS, NICE and Aetna in the US are analysed.

This study was intended to identify and analyse inefficiencies and bottlenecks that undermine health systems' sustainability and potential policy solutions to tackle them.

Consulting

Founded in 2002, OHE Consulting
provides client-focused, specialised
expertise on policy and strategic issues
affecting the delivery of health care
and the future of the pharmaceutical
and life sciences industries
.

We are dedicated to providing objective,
independent advice to help
our clients achieve their objectives.

O’Neill, P., Puig-Peiro, R., Mestre-Ferrandiz, J. and Sussex, J.

Consulting Report
October 2012

Since 1996, in its yearly PPRS Report to Parliament, the Department of Health in England has published international price comparisons of branded medicines used in the primary care setting. OHE Consulting uses the same methodology in this report to update comparisons through 2011.

Pages

Subscribe to RSS - Consulting Report